- Moderna stock slides again as investors lose faith.
- MRNA shares also suffering as UK fully opens up and Biden says normal is on the way.
- Moderna lacks alternative revenue streams.
FXStreet had turned bearish on this stock after resutls in November, but the emergence of the Omicron variant did change things somewhat. Moderna (MRNA) shares spiked as panic gripped markets and Omicron was an unknown entity.
The shares quickly spiked to nearly $380 from a post-earnings low of $220. However, Moderna put in a bearish shooting star candle that signified impending losses. The news was finally confirmed in our view when on December 20 Moderna said its jab was effective against Omicron. Moderna shares spiked intraday but actually closed 6% lower as investors ditched the name.
The reason as we now apparently know is that it appears Omicron is much less serious that other variants. More transmissable, yes, but the variant results in much fewer hospitalizations. Experts have now come to the conclusion that this is the end game for covid. This will be the final covid winter. This appears to have gotten confirmtaion from the UK yesterday as emabttled Prime Minister Johnson gets to luckily deflect attention away from him by announcing an end to restrictions. In the US President Biden says things are nearly back to normal. Europe is a little further behind, but already some countries such as Ireland are significantly easing restrictions.
Moderna Stock News
Moderna cracked below key support at $188 when it lost nearly 7% yesterday. Markets are not in a charitable mood, and increased attention is now being focused on potential short names and dumping high growth stocks. FXStreet has identified before the one-trick pony that MRNA potentially is. It is hugely reliant on covid vaccines for revenue. It does have some other products in the pipeline as shown below, but none are yet commercial.
Source: Moderna www.modernatx.com/pipeline
Moderna Stock Forecast
$188.40 was a big level going back to February of last year. The stock eventually broke above in summer 2021 and staged a successful pullback test before marching higher. Now that it is broken, the next target is $157.70 and then some decent volume support at $147. Resistance at $211 is the short-term pivot.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stays in positive territory above 1.0850 after US data
EUR/USD clings to modest daily gains above 1.0850 in the second half of the day on Friday. The improving risk mood makes it difficult for the US Dollar to hold its ground after PCE inflation data, helping the pair edge higher ahead of the weekend.
GBP/USD stabilizes above 1.2850 as risk mood improves
GBP/USD maintains recovery momentum and fluctuates above 1.2850 in the American session on Friday. The positive shift seen in risk mood doesn't allow the US Dollar to preserve its strength and supports the pair.
Gold rebounds above $2,380 as US yields stretch lower
Following a quiet European session, Gold gathers bullish momentum and trades decisively higher on the day above $2,380. The benchmark 10-year US Treasury bond yield loses more than 1% on the day after US PCE inflation data, fuelling XAU/USD's upside.
Avalanche price sets for a rally following retest of key support level
Avalanche (AVAX) price bounced off the $26.34 support level to trade at $27.95 as of Friday. Growing on-chain development activity indicates a potential bullish move in the coming days.
The election, Trump's Dollar policy, and the future of the Yen
After an assassination attempt on former President Donald Trump and drop out of President Biden, Kamala Harris has been endorsed as the Democratic candidate to compete against Trump in the upcoming November US presidential election.